Literature DB >> 18566749

Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas.

Minoru Miyashita1, Shin-Ichi Miyatake, Yoshio Imahori, Kunio Yokoyama, Shinji Kawabata, Yoshinaga Kajimoto, Masa-Aki Shibata, Yoshinori Otsuki, Mitsunori Kirihata, Koji Ono, Toshihiko Kuroiwa.   

Abstract

Here we demonstrate that differentiation between glioblastoma (GB) tumor progression (TP) and radiation necrosis (RN) can be achieved with fluoride-labeled boronoalanine positron emission tomography (F-BPA-PET). F-BPA-PET images were obtained from histologically verified 38 GB, 8 complete RN, and 5 RN cases with partial residual tumors. The lesion/normal (L/N) ratios for these groups were 4.2 +/- 1.4, 1.5 +/- 0.3, and 2.0 +/- 0.3, respectively. Ten GB patients underwent F-BPA-PET twice (once before and once after radiation treatment) due to enlargement of the original lesion or the development of new lesions post radiation. The L/N ratios of ten original site lesions had decreased by the second PET, and these lesions were revealed to be RN. In contrast, the L/N ratios of two lesions distant from the original site increased, and these lesions were revealed as cases of TP. Repeat PET imaging was found to be useful for evaluating changes in GB-associated tumor activity with respect to the treatment received.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566749     DOI: 10.1007/s11060-008-9621-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?

Authors:  Ulrich Hermanto; Erik K Frija; Mingfwu J Lii; Eric L Chang; Anita Mahajan; Shiao Y Woo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-08       Impact factor: 7.038

2.  18F-FDG PET and PET/CT in fever of unknown origin.

Authors:  Johannes Meller; Carsten-Oliver Sahlmann; Alexander Konrad Scheel
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.

Authors:  S Delanian; S Balla-Mekias; J L Lefaix
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

4.  Extraordinarily high F-18 FDG uptake caused by radiation necrosis in a patient with nasopharyngeal carcinoma.

Authors:  Guang-Uei Hung; Shih-Chuan Tsai; Wan-Yu Lin
Journal:  Clin Nucl Med       Date:  2005-08       Impact factor: 7.794

Review 5.  Fluorinated amino acids for tumour imaging with positron emission tomography.

Authors:  Peter Laverman; Otto C Boerman; Frans H M Corstens; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01-11       Impact factor: 9.236

6.  Treatment of radiation-induced nervous system injury with heparin and warfarin.

Authors:  M J Glantz; P C Burger; A H Friedman; R A Radtke; E W Massey; S C Schold
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

7.  Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas.

Authors:  Yoshinobu Takahashi; Yoshio Imahori; Katsuyoshi Mineura
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

8.  Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis.

Authors:  Y Sonoda; T Kumabe; T Takahashi; R Shirane; T Yoshimoto
Journal:  Neurol Med Chir (Tokyo)       Date:  1998-06       Impact factor: 1.742

9.  Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy.

Authors:  K Ishiwata; T Ido; A A Mejia; M Ichihashi; Y Mishima
Journal:  Int J Rad Appl Instrum A       Date:  1991

Review 10.  The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases.

Authors:  P C Burger; M S Mahley; L Dudka; F S Vogel
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

View more
  22 in total

1.  Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma.

Authors:  Natsuko Kondo; Rolf F Barth; Shin-Ichi Miyatake; Shinji Kawabata; Minoru Suzuki; Koji Ono; Norman L Lehman
Journal:  J Neurooncol       Date:  2017-05-22       Impact factor: 4.130

2.  The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

Authors:  Naosuke Nonoguchi; Shin-Ichi Miyatake; Motoi Fukumoto; Motomasa Furuse; Ryo Hiramatsu; Shinji Kawabata; Toshihiko Kuroiwa; Motomu Tsuji; Manabu Fukumoto; Koji Ono
Journal:  J Neurooncol       Date:  2011-06-18       Impact factor: 4.130

3.  Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.

Authors:  Motomasa Furuse; Shinji Kawabata; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  J Neurooncol       Date:  2010-08-07       Impact factor: 4.130

4.  Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Kunio Yokoyama; Toshihiko Kuroiwa; Hiroyuki Michiue; Yoshinori Sakurai; Hiroaki Kumada; Minoru Suzuki; Akira Maruhashi; Mitsunori Kirihata; Koji Ono
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

5.  Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Naosuke Nonoguchi; Kunio Yokoyama; Toshihiko Kuroiwa; Hideki Matsui; Koji Ono
Journal:  Neuro Oncol       Date:  2009-03-16       Impact factor: 12.300

6.  Synthesis and cellular studies of polyamine conjugates of a mercaptomethyl-carboranylporphyrin.

Authors:  N V S Dinesh K Bhupathiraju; M Graça H Vicente
Journal:  Bioorg Med Chem       Date:  2012-11-17       Impact factor: 3.641

Review 7.  Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis.

Authors:  T Nihashi; I J Dahabreh; T Terasawa
Journal:  AJNR Am J Neuroradiol       Date:  2012-11-01       Impact factor: 3.825

8.  Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: Qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions.

Authors:  Yasunori Ariyoshi; Masashi Shimahara; Yoshihiro Kimura; Yuichi Ito; Takeshi Shimahara; Shin-Ichi Miyatake; Shinji Kawabata
Journal:  Oncol Lett       Date:  2011-03-10       Impact factor: 2.967

9.  Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.

Authors:  Shin-Ichi Miyatake; Motomasa Furuse; Shinji Kawabata; Takashi Maruyama; Toshihiro Kumabe; Toshihiko Kuroiwa; Koji Ono
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

Review 10.  Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer.

Authors:  Rolf F Barth; M Graca H Vicente; Otto K Harling; W S Kiger; Kent J Riley; Peter J Binns; Franz M Wagner; Minoru Suzuki; Teruhito Aihara; Itsuro Kato; Shinji Kawabata
Journal:  Radiat Oncol       Date:  2012-08-29       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.